Eptifibatide
Aliases: Integrilin
Last verified: 2026-09-23
The short version
A cyclic heptapeptide designed from snake venom — a GP IIb/IIIa inhibitor; emergency cardiology (ACS, PCI) against platelet aggregation.
Identity & type
- Molecular type
- analog
- Origin
- A cyclic heptapeptide designed from snake venom — a GP IIb/IIIa inhibitor; emergency cardiology (ACS, PCI) against platelet aggregation.
Mechanism of action
Blocks fibrinogen binding to platelet GP IIb/IIIa.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. IV bolus 180 mcg/kg + infusion 2 mcg/kg/min.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
IV bolus 180 mcg/kg + infusion 2 mcg/kg/min. Integrilin: a hospital antiplatelet drug in acute coronary syndrome — reduces ischemic events during PCI.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Integrilin: a hospital antiplatelet drug in acute coronary syndrome — reduces ischemic events during PCI.
Protocol — official vs community
Official / label
Integrilin (acute coronary syndrome / PCI): 180 mcg/kg IV bolus, then continuous infusion of 2 mcg/kg/min; in PCI a second 180 mcg/kg bolus is given 10 minutes after the first. Infusion duration is indication-based (up to 18–24 h after PCI, up to 96 h in medically managed ACS per the label).
Duration: Hours to days — a periprocedural drug. CrCl <50 mL/min: reduce infusion to 1 mcg/kg/min.
GP IIb/IIIa blockade is the strongest antiplatelet intervention available, and bleeding plus acute thrombocytopenia are its direct cost. Cath-lab-only agent; no community use exists.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Approved 1998; standard in select PCI scenarios.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Bleeding, thrombocytopenia.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials